Dynavax Technologies (NASDAQ:DVAX) Sees Strong Trading Volume – Here’s What Happened

Dynavax Technologies Co. (NASDAQ:DVAX) shares saw strong trading volume on Thursday . 8,516,987 shares were traded during mid-day trading, an increase of 328% from the previous session’s volume of 1,988,812 shares.The stock last traded at $14.27 and had previously closed at $14.01.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th.

Dynavax Technologies Trading Up 0.4 %

The company has a fifty day simple moving average of $13.01 and a two-hundred day simple moving average of $12.21. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.79 billion, a P/E ratio of 80.00 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The firm had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Institutional Trading of Dynavax Technologies

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares during the last quarter. US Bancorp DE increased its position in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Dynavax Technologies in the fourth quarter valued at about $35,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the third quarter valued at about $45,000. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.